Peanut is a common childhood allergen in the United States (US). According to recent estimates approximately 1.4-4.5% of children suffer from peanut allergy. It is more common in males (1.7% versus 0.8%), people with lower income (1.7% versus 1.2%), and there are race/ethnic disparities in the prevalence of peanut allergies (2.8% non-Hispanic blacks, 1.7% Hispanics, and 0.9% non-Hispanic whites). In addition, peanut allergy is the leading cause of death from anaphylaxis due to food, particularly in teenagers, though the rate is low. The national food allergy death registry reports fewer than four deaths per year over the past 10 years in the US.
The independent appraisal committee highlighted the importance of non-clinical benefits and contextual considerations when evaluating AR101 and Viaskin Peanut. The potential short-term budget impact lead ICER to issue an Access and Affordability Alert.
Treatments of Interest:
- peanut immunotherapy (Viaskin® Peanut, DBV Technologies)
- peanut immunotherapy (PalforziaTM, Aiummune)
Below you will find the final documents from the assessment review process:
“Currently, there are no FDA-approved treatments for patients with peanut allergy, and the potential for accidental exposure to peanuts can create tremendous anxiety for patients and their caregivers. However, while Viaskin Peanut, AR101, and OIT have all been shown to desensitize patients to the allergen, each one of these approaches is also associated with increased allergic reactions and use of epinephrine. Caregivers and patients must remain vigilant about avoiding peanuts even while on desensitization therapy, and future clinical trials will need to demonstrate whether long-term benefits of these approaches outweigh their short-term risks.”